Martin Burian

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck

Csilla Neuchrist, Boban M. Erović, Alessandra Handisurya et al. · Head & Neck · 2003 · 117 citations

Superimposed high-frequency jet ventilation (SHFJV) for endoscopic laryngotracheal surgery in more than 1500 patients

A Rezaie-Majd, Wolfgang Bigenzahn, D.-M. Denk et al. · British Journal of Anaesthesia · 2006 · 94 citations · Full text

Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double‐blind, randomized, placebo‐controlled trial

Dominik Riss, Martin Burian, Axel Wolf et al. · Head & Neck · 2014 · 82 citations